Programs of tissue differentiation are likely controlled by factors regulating gene expression and protein degradation. In muscle, the degradation of the muscle transcription factor MyoD and its inhibitor Id1 occurs via the ubiquitin-proteasome system. E12 and E47, splice products of the E2A gene, interact with MyoD to activate transcription of the muscle program and are also degraded by the ubiquitin-proteasome system (t 1/2 ¼ B6 h). E12 and E47 each contain two regions of basic amino acids, which, when mutated, lead to cytoplasmic accumulation of the proteins. These NLS mutants (E12 NLS , E47 NLS ) are degraded with a half-life similar to the wild-type proteins. In nonmuscle cells, cotransfection of either E12 or E47 with MyoD extended MyoD's half-life from B1 to B4 h. In addition, cotransfection of either E12 or E47 with Id1 led to a marked reduction in Id1's degradation rate from t 1/2 of B1 to B8 h. Furthermore, the cotransfection of NLS deficient mutants of MyoD or Id1 with E12 or E47 resulted in altered intracellular localization of the proteins largely dependent upon the E12 or E47 moiety. Cotransfection of wild-type MyoD or Id1 with NLS deficient mutants of E12 or E47 also led to an altered intracellular localization of MyoD and Id1. These results demonstrate in vivo that E12 and E47 modulate both MyoD and Id1 degradation and may have implications for the physiological regulation of muscle development.
Introduction
Programs of tissue differentiation, such as muscle, which are dependent upon the levels of specific transcription factors, are likely to be regulated by factors balancing gene expression with protein turnover. While much is known about gene expression patterns, the cell biological factors determining the cell specific localization and turnover (i.e. degradation) of their proteins is much less well understood. The ubiquitin-proteasome system is responsible for the degradation of many short-lived cellular proteins including transcription factors, tumor suppressors, and cell cycle regulators. This pathway is initiated by the activation of ubiquitin by the ubiquitinactivating enzyme, E1. This is followed by transfer of ubiquitin by E2, ubiquitin-conjugating enzyme, to the substrate specific E3, or ubiquitin ligase. The E3 then delivers the ubiquitin to the substrate to be degraded. Ubiquitination occurs via an amide linkage to the e-amino group of an internal lysine of the protein (the lysine dependent pathway) or to its N-terminus (the Nterminus dependent pathway). A polyubiquitin chain is formed through successive rounds of activation, transfer and conjugation to the attached ubiquitin. The substrate-ubiquitin conjugate is then degraded by the 26S proteasome in an ATP-dependent manner. Isopeptidases cleave the ubiquitin chain, and single ubiquitin molecules are recycled.
Among the many short-lived proteins degraded by the ubiquitin-proteasome system are several transcription factors including MyoD, a key regulator of muscle differentiation. MyoD has been shown to be ubiquitinated and degraded by both the N-terminus and lysine-dependent pathways in both the cytoplasm and the nucleus although the extent of degradation in each cellular compartment differs (Lingbeck et al., 2003) .
MyoD, like many other transcription factors, has high-affinity binding partners. The Id proteins, inhibitors of DNA binding, comprise a family of four helixloop-helix proteins (Id 1-4) that do not contain a basic region for DNA binding, thus when dimerized with MyoD they form a complex that is unable to bind DNA and activate transcription. Of the Id proteins, Id1 has been reported to be the most active in binding MyoD (Langlands et al., 1997) . A decreased rate of Id1 degradation via the ubiquitin-proteasome system was observed upon cotransfection of MyoD and Id1 into HeLa cells, suggesting a dynamic interplay of these two factors (Trausch-Azar et al., 2004).
Other high-affinity 'activating' binding partners of MyoD are E12 and E47, splice variants of the E2A gene product. E12 and E47 are also inhibited by the Id family of proteins. In order to directly determine the effect of E12 and E47 on the degradation of MyoD and Id1, we transfected these proteins into a cell line that does not express muscle regulatory factors at a detectable level. With this, we show that E12 and E47 are degraded by the ubiquitin-proteasome system in the cell nucleus and that E12 and E47 regulate the degradation of both MyoD and Id1.
Results
E12 and E47 are localized to the nucleus in HeLa cells following transfection (Figure 1a ). The half-life of each protein was determined by treatment of the cells with cycloheximide (CHX), B16-20 h after transfection, to inhibit further protein synthesis. Cells were lysed at 0, 0.5, 1, 2 and 3 h and the amount of protein at each time point was determined via Western blot analysis. MG132, a proteasome inhibitor, or leptomycin B (LMB), an inhibitor of the CRM-1 dependent nuclear export pathway, was added along with the CHX in replicate samples to determine the degradation rate of E12 and E47 under conditions of proteasome inhibition or inhibited nuclear export. As seen in Figure 1b , E12 and E47 are degraded with a half-life of 5.7 and 5.8 h, respectively. The average half-life from several degradation experiments was 5.870.6 h for E12 and 6.570.7 h for E47. The half-life of both proteins was increased to >10 h with the addition of MG132 and relatively unchanged with the addition of LMB (data not shown).
Like other transcription factors, such as MyoD, E12 and E47 are synthesized in the cytoplasm and translocated into the nucleus via a nuclear localization signal (NLS). Previously, it has been reported that E12 and E47 contain an NLS in the N-terminus, however, no site-directed mutants of the NLS have been reported. By scanning the amino-acid sequence in the N-terminal region, a sequence high in basic amino-acid (K or R) content was noted between amino acids 152 through 169 and was considered as a potential NLS. Mutagenesis of amino acids K165, K166, R168 and K169 to alanine in E12 produced a protein that was 55% cytoplasmic.
An additional region of high basic charge density in E12 and E47 exists in the basic, DNA binding region of the proteins, similar to the NLS of MyoD (Lingbeck et al., 2003) . The lysines and arginines in this region (amino acids 542 through 557 for E12 and 539 through 554 for E47) were mutated to alanine along with the amino-acid region 165 through 169 previously mentioned. The resulting species were termed E12 NLS and E47 NLS . These proteins were 74 and 78% cytoplasmic, respectively (Figure 2a) . Interestingly, mutation of E47's amino-acid region 539 through 554 alone had no effect on the inhibition of nuclear import (data not shown). Unlike the NLS deficient mutant of MyoD (MyoD NLS ) (Lingbeck et al., 2003) , E12 NLS and E47 NLS were not significantly nuclear upon LMB treatment (7 and 16%, respectively, Figure 2a ). The rate of degradation of the E12 NLS was determined to be 5.570.8 h while that of E47 NLS was 5.970.7 h (for example, see Figure 2b ). To determine whether E12 and E47 interact with MyoD in vivo and to determine which protein plays the dominant role in the localization of the heterodimer, we transfected cells with various E12 or E47 and MyoD constructs. Initially, we selected MyoD NLS and E12 or E47 and evaluated the localization of the two proteins. MyoD NLS , when expressed alone is B9% nuclear; however, when cotransfected with one of the E2A proteins MyoD becomes markedly more nuclear, >95% with either E12 or E47 (Table 1, Figure 3a -e). The localization of E12 and E47 (100% nuclear) did not change At B18 h after transfection with either E12 or E47 cDNA, HeLa cells were treated with cycloheximide and lysed at 0, 0.5, 1, 2 and 3 h. Lysates were evaluated by SDS-PAGE followed by Western blot for E12 or E47. The pixels in each band were measured and normalized so that the number of pixels at time ¼ 0 was 100%. The log 10 of the % pixels was plotted versus the time in hours. The half-life was determined from the log of 50%. The t 1/2 for E12 was 5.7 h and the t 1/2 for E47 was 5.8 h significantly when cotransfected with MyoD NLS ( Figure 3f -j). Similar results were seen with wild-type Id1. When cotransfected with NLS-deficient E12 or E47, Id1 went from 72% nuclear to B45% nuclear (Table 1) . E12 NLS and E47 NLS became slightly more nuclear (from B2 to 8%) when cotransfected with Id1 (Table 1) .
In order to determine the effect of E12 and E47 on the degradation of MyoD in vivo, we cotransfected MyoD with E12 or E47 into HeLa cells in a 1 : 1 molar ratio. As seen in Figure 4 , the t 1/2 of MyoD increased from B1 to B4 h in the presence of E12 or E47. The t 1/2 of E12 increased from 5.470.4 to 1172 h and that of E47 increased from 6.570.7 to 1072 h in the presence of MyoD (Table 2) . Actin was used as a control for ubiquitin-proteasome degradation.
Similar experiments were performed with Id1 and the E2A proteins. Id1 is markedly stabilized in the presence of either E12 or E47 as seen by the increase in the t 1/2 from B1 to B8 h (Table 3; for example see Figure 5 ). In addition, an increase in the t 1/2 of E12 from 5.470.4 to 1271 h and in the t 1/2 of E47 from 6.570.7 to 1071 h was seen in the presence of Id1 (Table 3) .
In order to further demonstrate that E2A proteins interact with MyoD or Id1, a coimmunoprecipitation assay was performed. As seen in Figure 6 , panel b, immunoprecipitation of the cell lysate with antibody to cDNA, cells were treated with cycloheximide and lysed at 0, 0.5, 1, 2 and 3 h. Analysis was performed as described in the legend to Figure 1 . The t 1/2 for E12 NLS was 5.5 h and the t 1/2 for E47 NLS was 5.8 h The present study also suggests that the ubiquitinproteasome pathway governs the cellular degradation of E12 and E47, similar to its role in MyoD and Id1 degradation (Lingbeck et al., 2003; Trausch-Azar et al., 2004) . There is, however, little data on the molecular mechanisms involved. The ubiquitin-conjugating enzyme (E2) responsible for ubiquitin-proteasome dependent degradation of E12 and E47 is Ubc9 (Kho et al., 1997) . Ubc9 interacts with amino acids 477-530 in the C-terminus of E12 and E47. Removal of these amino acids from E47 led to a more stable protein while HeLa cells were transfected with E12 or E47, MyoD, or both as indicated. The subcellular localization of each expressed protein was determined via immunofluorescence and the rate of degradation of each protein was determined as described. Error is reported as 7s.e.m. HeLa cells were transfected with E12 or E47, Id1, or both as indicated. The subcellular localization of each expressed protein was determined via immunofluorescence and the rate of degradation of each protein was determined as described. Error is reported as 7s.e.m. Figure 5 Half-life of Id1 following transfection with E12 or E47. At B18 h after transfection of HeLa cells with Id1 alone or Id1 plus E12 or E47 in a 1 : 1 molar ratio, cells were treated with cycloheximide and analysis was carried out as described in the legend to Figure 1 . The t 1/2 of Id1 alone was 0.9 h and increased to B8 h when transfected with either E12 or E47
E12 and E47 modulate MyoD and Id1 degradation JM Lingbeck et al leaving DNA binding and transcriptional activity unaffected (Kho et al., 1997; Huggins et al., 1999) . This region is immediately adjacent to that which we identified as a portion of the nuclear localization sequence. In addition, this sequence is high in PEST residues (proline, glutamic acid, serine and threonine) and phosphorylation of one of these sites may signal degradation (Huggins et al., 1999) as does the phosphorylation of S200 in MyoD (Song et al., 1998) . Our present study demonstrates that E12 and E47 are localized exclusively to the nucleus and degraded by the ubiquitin-proteasome system in vivo with a half-life of B6 h (Figure 1 ). This appears to be somewhat slower than the 1 h half-lives for E12 and E47 in COS7 and NIH3T3 cells reported by Kho et al. (1997) . In addition, Deed et al. (1996) reported a half-life of 24 h for E47 in COS7 cells. The apparent difference in these results is not clear, but may be attributed to different experimental approaches and/or cell types analysed. However, previous results from our laboratory as well as from others demonstrate similar degradation rates for MyoD whether determined via Western blotting following CHX treatment described in Materials and methods or via biosynthetic radiolabeling pulse-chase analysis (Breitschopf et al., 1998; Floyd et al., 2001; Tintignac et al., 2005) .
The effect of LMB, which inhibits nuclear export through the CRM-1 dependent pathway only, marginally altered the half-life of E12 and E47. This suggests that E12 and E47 are ubiquitinated and degraded in the nucleus, similar to that seen with its class B binding partner, MyoD (Floyd et al., 2001) . Some nuclear factors such as IkBa (Rodriguez et al., 1999) and p27 kip1 (Tomoda et al., 1999) are exported from the nucleus prior to degradation, while others such as ligandactivated Smad3 (Fukuchi et al., 2001 ) are ubiquitinated in the nucleus and exported to the cytoplasm for degradation.
Transport of proteins across the nuclear envelope is facilitated by one or more NLSs. Studies of E12 and E47 suggested the presence of an NLS in that an N-terminal truncation of E12 yielded accumulation of the mutant protein in the cytoplasm (Deed et al., 1996) . In the present study, we mutated positively charged residues between amino acids 165 through 169 of E12 to alanine. This resulted in an alteration of localization in that the protein was largely localized to the cytoplasm (55% cytoplasmic). Further inhibition of nuclear import was seen when the basic amino acids in the DNA binding region (amino acids 539 through 557) were mutated to alanine, similar to that observed with the NLS in MyoD (Lingbeck et al., 2003) . Mutagenesis of amino acids 165-169 along with amino acids 539-557 produced the resultant proteins E12 NLS and E47
NLS
, which were 74 and 78% cytoplasmic, respectively. Similar findings were recently seen with the transcription factor TBX5. TBX5 contains two NLSs separated by >200 amino-acid residues with both sequences necessary for complete nuclear localization of the protein (Collavoli et al., 2003) . Unlike MyoD NLS , LMB treatment did not result in nuclear accumulation of E12 NLS or E47 NLS (Figure 2a ). This suggests that NLS deficient E2A proteins do not undergo CRM-1-dependent nuclear cytoplasmic shuttling or that they do so much less rapidly than MyoD NLS such that a significant increase in nuclear accumulation is not seen after only 2 h with LMB. The half-lives of E12 NLS and E47 NLS are similar to their wild-type counterparts (5.570.8 and 5.970.7 h, respectively) (for example, see, Figure 2b ).
E12 and E47 are able to chaperone the NLS-deficient proteins MyoD (MyoD NLS ) and Id1 (Id1 NLS ) into the nucleus. This suggests an interaction among these proteins in vivo. Surprisingly, neither Id1 nor MyoD were able to significantly direct E12 NLS or E47 NLS to the nucleus (Figure 3f-j) . However, MyoD, and to a larger extent Id1, were retained within the cytoplasm by E12 NLS and E47
. As these proteins are all synthesized in the cytoplasm prior to nuclear entry, it is likely that these results imply cytoplasmic retention (via E12 NLS or E47 NLS ) as opposed to nuclear export. However, kinetic flux studies have not been performed herein. One possible explanation for these results is that the NLS of MyoD or Id1 is sterically masked when bound to E12 or E47 (or E12 NLS or E47 NLS ), and therefore the NLS (or absence of NLS) of E12 or E47 directs the localization.
MyoD and Id1 did not significantly direct E12 NLS or E47 NLS to the nucleus, nor did E12 NLS or E47 NLS fully retain MyoD or Id1 in the cytoplasm. However, depending upon the protein pair, the differences in subcellular localization are striking. For example, MyoD NLS goes from 9 to 96% nuclear in the presence of E12, whereas wild-type MyoD, which alone is 99% nuclear, remains at 89% nuclear in the presence of E12 NLS (Table 1) . These results taken together suggest that subcellular localization (nuclear or cytoplasmic) of Not only can E12 and E47 affect the subcellular localization of MyoD and Id1, they also influence their degradation. Deed et al. (1996) reported an increase in the rate of degradation of E47 when cotransfected with Id3, while Id3's rate of degradation was slowed. Our data show that both E47 and Id1 are stabilized when cotransfected into HeLa cells. In fact, Id1 is markedly stabilized from t 1/2 B1 h to greater than B8 h in the presence of E12 or E47 (Table 3; for example see, Figure 5 ).
The Western blot also shows the presence of two bands for Id1, which is likely due to post-translational modification of the protein with the upper band being the active, phosphorylated form. When cotransfected with E12 or E47, a marked stabilization of the lower band is seen with respect to the upper band. It may be that binding to E12 or E47 inhibits phosphorylation of Id1. Although phosphorylation does not affect heterodimer formation with E47 (Nagata et al., 1995) , it may be that phosphorylation is necessary for the degradation of Id1 similar to that seen with MyoD (Song et al., 1998) .
MyoD is also stabilized in the presence of either E2A protein (increase in t 1/2 from B1 to 4 h), but not to the extent of Id1. This marked stabilization of Id1 compared to MyoD may reflect a higher affinity of Id1 compared to MyoD for E2A proteins. Indeed, Id1 appears to bind E2A proteins more strongly than MyoD (Benezra et al., 1990; Sun et al., 1991; Langlands et al., 1997) . Furthermore, Id proteins sequester E2A proteins and prohibit them from binding to MyoD-like proteins (Benezra et al., 1990; Sun et al., 1991) . Weaker binding of MyoD to Id1 may in part explain why MyoD does not stabilize Id1 to the same extent as E2A proteins (Trausch-Azar et al., 2004) .
In order to establish that changes in t 1/2 upon cotransfection of the various constructs was due to the interactions of the specific proteins, we cotransfected Id1 and an unrelated nuclear transcription factor, FoxJ1, into HeLa cells. The resultant half-life of Id1 was altered slightly from 0.9 to 0.6 h in the presence of FoxJ1. The half-life of FoxJ1 in the presence of Id1 as 0.4 h compared to 0.5 h when transfected alone (data not shown). These results show that the changes in half-life of Id1, MyoD and the E2A proteins are likely a result of interactions between these proteins and not due merely to cotransfection. It is also not likely that the increase in the half-lives is due to saturation of the proteasome from protein overexpression as previous studies in our laboratory and others showed that overexpression of both MyoD and Id1 increased only the half-life of Id1 and while the halflife of MyoD remain unchanged (Trausch-Azar et al., 2004) .
Further evidence for direct interaction between the transcription factors can be seen in the coimmunoprecipitation assay of MyoD and E47 (Figure 6 ). Incubation of cell lysates with an antibody for E47 also brought down MyoD indicating that these two proteins interact. Future studies will examine the interaction of these factors using fluorescence resonance energy transfer (FRET) in both the cytoplasm and the nucleus.
Since programs of tissue differentiation, such as muscle, are dependent upon the levels of specific transcription factors, they are likely to be regulated by factors balancing gene expression with protein degradation. While much is known about gene expression patterns, the cell biological factors determining the cell specific localization and degradation of their protein are much less well understood. We have shown that E12 and E47 are able to regulate both the rates of degradation as well as subcellular localization of MyoD and Id1 and that Id1, to a greater extent than MyoD, is able to regulate the rate of degradation of E12 and E47. Our previous data showed that MyoD modulates Id1 degradation. Thus, taken together, these results strongly suggest that for at least this network of interactive proteins, both subcellular localization and regulation of protein degradation via the ubiquitin-proteasome system, are likely to be important in tissue differentiation and developmental programs.
Materials and methods

Plasmids and construction of NLS mutants
Wild-type MyoD and MyoD NLS , both in the pCIneo vector have been previously described (Lingbeck et al., 2003) . Wildtype Id1 and Id1 NLS , both in pcDNA3 have been described earlier (Trausch-Azar et al., 2004) . E12 in pGK9 and E47 in pCMV were gifts from Gregory Kato. Both E12 and E47 were later cloned into pCIneo. NLS mutants of E12 and E47 were prepared using the QuikChange site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions. Mutants were confirmed by sequencing using Big Dye Version 3.1 (ABI Biosystems).
Cell culture
HeLa cells, which do not express MyoD, E12, E47 or Id1 at considerable levels, were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 2 mM L-glutamine and antibiotics (100 U/ml penicillin G and 100 mg/ml streptomycin) (Life Technologies Inc.) and maintained in a humidified chamber at 371C and 5% CO 2 . Transient transfections (efficiency 40-60%) were performed using the Fugene 6 reagent (Roche) and cells were analysed 16-20 h later.
Immunofluorescent localization of E12, E47, E12
NLS and E47 NLS Subcellular localization of E12, E47 and their NLS mutants in HeLa cells was determined by indirect immunofluorescence using mouse monoclonal anti-E12/E47 (1 : 200 dilution, BD Pharmingen) followed by incubation with TRITC-conjugated donkey anti-mouse IgG (heavy and light chain) (Jackson Immunochemical). MG132 (20 mM, Peptides International) or LMB (10 nM, Sigma) were added to cells 2 h prior to fixation where indicated. MG132 was prepared as a 10 mM stock solution in DMSO. LMB was prepared as a 10 mM solution in ethanol. Cells were observed using a Zeiss Axioscope microscope and 10-20 random fields of each culture condition were photographed (magnification Â 40) using a Zeiss Axiocam digital camera.
Determination of degradation of E12 and E47 in vivo As previously described (Floyd et al., 2001; Lingbeck et al., 2003; Trausch-Azar et al., 2004) , 16-20 h after transfection, HeLa cells were incubated with CHX (100 mg/ml, Sigma) to inhibit further protein synthesis. MG132 (20 mM) or LMB (10 nM) were added along with CHX as noted. The cells were lysed after 0, 0.5, 1, 2 and 3 h in PBS containing 5% Igepal, 1 mM EDTA, 1 mM DTT, 2 mM PMSF, 2.5 mg/ml leupeptin and 1 mM pepstatin for at least 30 min after which cells were sonicated, then centrifuged at 14 000 r.p.m. for 10 min at 41C in an Eppendorf microcentrifuge to remove cellular debris. The lysates were mixed with an equal amount of Laemmli sample buffer (Bio-Rad) and equal amounts of sample were run on a 12% Tris-HCl gel (Bio-Rad) and electroblotted onto nitrocellulose (Osmonics). The blots were probed with polyclonal anti-E12 or anti-E47 antibody (1 : 100 dilution, Santa Cruz Biotechnologies) followed by incubation with a secondary horseradish peroxidase-conjugated antibody and detection by chemiluminescence (Amersham Pharmacia Biotech). The resulting bands were quantitated using the Kodak EDAS system and the data was graphed using the Excel graphing program (Microsoft). Since ubiquitin-mediated degradation is a stochastic process, data were plotted as log of % pixels versus time for ease of calculation of the degradation rate. The degradation rate is expressed as half-life (t 1/2 ), the time for degradation of 50% of the sample. Each of the constructs was evaluated by three to six independent determinations of t 1/2 . The data are expressed as mean7s.e.m.
Localization of E12 and E47 with MyoD and Id1
HeLa cells were cotransfected with E12 or E47 and MyoD or Id1 in a 1 : 1 molar ratio. Subcellular localization was determined by indirect immunofluorescence using mouse monoclonal anti-E12/E47 (1 : 200 dilution, BD Pharmingen) followed with a TRITC-conjugated donkey anti-mouse IgG (heavy and light chain) (Jackson Immunochemical). MyoD was probed with the rabbit polyclonal anti-MyoD (1 : 100 dilution, Santa Cruz, M-318) and a rabbit polyclonal anti-Id1 was used for the detection of Id1 (1 : 100 dilution, Santa Cruz, C-20). Both were followed by incubation with a FITCconjugated goat anti-rabbit IgG (heavy and light chain) (Jackson Immunochemical). Cells were observed using a Zeiss Axioscope microscope and 10-20 random fields of each culture condition were photographed at Â 40 magnification using a Zeiss Axiocam digital camera. Cells were scored and the percent cells expressing nuclear E12, E47, MyoD or Id1 was determined as previously described (Sachdev et al., 2000; Yagita et al., 2002; Lingbeck et al., 2003) . Specifically, cells were scored according to the cellular localization of E12, E47, MyoD or Id1 as predominately nuclear, predominately cytoplasmic, or distributed equally between the nucleus and the cytoplasm, similar to methods of Sachdev et al. (2000) and Yagita et al. (2002) . For each determination over 100 cells were scored from three to six independent transfections.
Degradation of E12 or E47 with MyoD or Id1
HeLa cells were cotransfected with E12 or E47 and MyoD or Id1 in a 1 : 1 molar ratio. At 16-20 h after transfection, the cells were incubated with CHX to inhibit further protein synthesis. The half-life experiments were carried out as previously described. The cell lysates were run on 12% Tris-HCl gels for E12, E47 or MyoD, and 18% for Id1 (Bio-Rad) and the blots were probed with polyclonal antibodies (Santa Cruz) to E12, E47, MyoD, or Id1 all at 1 : 100 dilutions. Incubation with a secondary horseradish peroxidase conjugated antibody followed and detection was by chemiluminescence (Amersham Pharmacia Biotech). Previously, we and others have determined the half-life of MyoD via biosynthetic radiolabeling and pulse-chase experiments as well as CHX block and Western immunodetection experiments. Both these techniques reveal that MyoD is degraded by the ubiquitin-proteasome pathway with a similar t 1/2 (Breitschopf et al., 1998; Floyd et al., 2001; Tintignac et al., 2005) .
Coimmunoprecipitation of E47 and MyoD
HeLa cells were transfected with E47 and MyoD in a 1 : 1 molar ratio. At B18 h after transfection, cells were lysed in PBS containing 0.5% Igepal, 1 mM EDTA, 1 mM DTT, 2 mM PMSF, 2.5 mg/ml leupeptin and 1 mM pepstatin for 30 min at 41C. Cells were scrapped into an Eppendorf tube, sonciated and spun at 14 000 r.p.m. at 41C for 10 min to remove cellular debris. The supernatant was precleared overnight at 41C with protein A-Sepharose (RepliGen). Immunoprecipitations were performed by incubation with polyclonal anti-E47 antibody (1 : 100 dilution, Santa Cruz Biotechnologies) followed by protein A-Sepharose. The beads were washed and the immunoprecipitates were run on a 12% Tris-HCl gel and analysed via Western blot. The blots were probed with monoclonal anti-MyoD antibody (1 : 20 dilution, NCLMyoD1; NovaCastra) followed by incubation with a secondary horseradish peroxidase-conjugated antibody and detected by chemiluminescence (Amersham Biosciences).
